Inhibition of heparin-binding
US5464815A · kind A · utility
52Cited by
13References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1994 |
| Grant date | Nov 7, 1995 |
| Priority date | — |
| Expiry date | Jun 6, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method for extending the plasma half-life of heparin-binding proteins by coadministering such proteins with a therapeutically acceptable compound capable of inhibiting their binding to a low affinity heparin-like binding site on the surface of cells. In one embodiment of the invention, the-heparin-binding protein is a selectin. The binding inhibitory compound can, for example, be a purified native heparin preparation, a heparin fragment, or another polyanionic compound, such as dextran sulfate, heparan sulfate, pentosan sulfate, or hyaluronate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.